Also from this source

You just read:

bioMerieux's THxID®-BRAF Test for Detection of 2 BRAF Mutations V600E and V600K in Late-Stage Metastatic Melanoma adopted by Clarient, a GE Healthcare Company

News provided by

bioMerieux, Inc.

Jan 28, 2014, 01:46 EST